Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB078 long-term extension in adults with C9ORF72-associated amyotrophic lateral sclerosis
NL-OMON49747Active, not recruiting
- Sponsor
- Biogen
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tadnersen in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Biogen. Primary endpoint: Incidence of adverse events and serious adverse events. Started Sep 2020; status: active, not recruiting.
02
Drugs
tadnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON49747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49747.